Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

GAR Helps Counter Legal Pitfalls of Cancer Screening, Diagnosis

June 1, 1996
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

WASHINGTON--Put GAR in your patients' records. It can prove extremely useful should you find yourself being sued for medical malpractice, Marvin A. Dewar, MD, JD, said at the National Conference on Prevention and Early Detection, sponsored by the American Cancer Society.

WASHINGTON--Put GAR in your patients' records. It can prove extremelyuseful should you find yourself being sued for medical malpractice,Marvin A. Dewar, MD, JD, said at the National Conference on Preventionand Early Detection, sponsored by the American Cancer Society.

GAR is an acronym for "general information, alternatives,risks"--three key points every physicians needs to discusswith patients before cancer screening or diagnosis,

Dr. Dewar, director, Family Practice Residency Program, the Universityof Florida College of Medicine, Gainesville, said that malpracticecases alleging that a physician delayed diagnosis or failed todiagnose a cancer continue to increase.

In a 1991 Florida study, Dr. Dewar and his colleagues found thatin cases involving primary care physicians, failure to diagnosecancer was the most common allegation, representing 16% of allpaid claims, at an average cost of $160,352. Failure to diagnosebreast cancer ranked first, followed by lung, prostate, and coloncancer.

One element in defending against such lawsuits is having and documentinga good informed consent process. And thus, he recommends rememberingGAR.

"Informed consent is a conversation that you as providershave with patients," Dr. Dewar said. "It is the understanding,the meeting of the minds between the patient and the provider.The documentation of the informed consent is not informed consent,but it is important from the legal protection standpoint."

He urged that physicians give each patient general information,explain the alternatives, describe the risks, and note this inthe patient's record.

"A plastic surgeon or a breast surgeon will dictate voluminousand detailed informed consent," Dr. Dewar said. "Atthe cancer detection level, you and I often don't have time todo that. Nonetheless, documentation is important, and I suggestthat you do it."

Impact of Practice Guidelines

Clinical practice guidelines have been the subject of much debateabout whether they increase the risk of malpractice litigationor protect providers and decrease the threat. In fact, such guidelinescan prove to be a mixed blessing. The most helpful practice guidelinesfor physicians, Dr. Dewar commented, are those that are widelyaccepted by the medical community.

In areas where guidelines diverge or conflict, practice recommendations"are not going to carry very much legal weight," hesaid, "because they will be just as confusing to the juryas they are to many providers and patients."

More relevant to malpractice suits are guidelines developed specificallyto address situations that commonly lead to litigation. But mostimportant, practice guidelines "have to be straightforwardand readily interpreted in the litigation setting," Dr. Dewarsaid.

For example, he said, the American Cancer Society's guidelinesfor screening intervals are very simple, clear, and easily understood."They will have more weight in a litigation setting thanwill more lengthy and confusing guidelines."

Defining Medical Negligence

Legally, to succeed in winning compensation in a malpractice suit,a patient must prove medical negligence, and this essentiallyconsists of four points.

First, an obligation must exist that the provider give a certainlevel of care; second, that duty must be breached; third, thatbreach must cause harm to the patient; and fourth, that harm mustinflict legally recognizable damage, such as loss of wages, onthe patient.

Originally, local medical standards served as the criteria fordetermining a physician's standard of care; now physicians facea national standard. "Although the resources may be different,the standard of care that you provide with those resources isgoing to be the same in Wisconsin as it is in Atlanta," Dr.Dewar commented.

However, physicians do have what attorneys call the "respectableminority rule" on their side. This is especially importantin such areas as prostate screening that are marked by scientificcontroversy and varying recommendations and practice guidelines.

"If the care decision that you go by is supported by whatwe call a respectable minority of the medical profession, then,in fact, you have not breached the duty of care," Dr. Dewarsaid. "So in an area where there is tremendous scientificdebate, the clinician is not going to be put on the hook, theoretically,for following one of the viable options."

However, where one practices can make a difference in the criteriafor proving harm, legally referred to as "causation."Most states use "the 51% rule," Dr. Dewar said, whichmeans that "the breach of duty had to be the probable causeof the injury, with a 51% chance that the failure to do something,or the doing of something that shouldn't have been done, led tothe injury."

A minority of states, including Illinois and West Virginia, usea more stringent rule, such as the physician's action resultingin "some loss of chance of a better outcome," and theserules work more to the plaintiff's advantage," he said.

The large majority of medical malpractice suits never stay thefull legal course from accusation to jury verdict, he said. Nationally,73% of medical malpractice cases end in settlement, with another10% dismissed by the courts.

One of physicians' greatest malpractice fears--the awarding ofpunitive damages--is actually quite rare in the health-care setting,Dr. Dewar said, since they require proof of willful and wantonnegligent conduct.

Articles in this issue

Psychosocial Oncology May Benefit From System Reform
Know Your Partners, Know Your Goals in Joint Ventures Between Hospitals and Universities
Managed Care Reform: Wait Until Next Year for House, Senate
Converting Quality of Life Data to 'Q' Scores Allows Comparisons
Shorter Paclitaxel Infusions Add to Neuropathy Risk
Breast Cancer Mortality Rates Down

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Related Content

While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 15th 2025
Article

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Numerically higher ORRs were reported in those who received treatment in the second line vs third line, in those with a CTFI of 90 days or more, and those without CNS metastasis.

Lurbinectedin Yields Responses in Various ES-SCLC Subgroups

Tim Cortese
September 15th 2025
Article

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 15th 2025
Podcast

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 15th 2025
Article

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC

Roman Fabbricatore
September 15th 2025
Article
Related Content

While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 15th 2025
Article

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Numerically higher ORRs were reported in those who received treatment in the second line vs third line, in those with a CTFI of 90 days or more, and those without CNS metastasis.

Lurbinectedin Yields Responses in Various ES-SCLC Subgroups

Tim Cortese
September 15th 2025
Article

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 15th 2025
Podcast

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 15th 2025
Article

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC

Roman Fabbricatore
September 15th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.